MONTREAL, QUEBEC--(Marketwire - June 10, 2008) - Ambrilia Biopharma Inc. (TSX: AMB) today unveiled during its Annual General Meeting its complete antivirals portfolio comprising of small molecules and peptides targeting HIV/AIDS, Hepatitis C and Influenza A, as well as highlighted the latest progress made in the strategic plan execution.
